MEP39208A - USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION - Google Patents

USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Info

Publication number
MEP39208A
MEP39208A MEP-392/08A MEP39208A MEP39208A ME P39208 A MEP39208 A ME P39208A ME P39208 A MEP39208 A ME P39208A ME P39208 A MEP39208 A ME P39208A
Authority
ME
Montenegro
Prior art keywords
hcg
ovarian hyperstimulation
controlled ovarian
controlled
hyperstimulation
Prior art date
Application number
MEP-392/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Yves Menezo
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of MEP39208A publication Critical patent/MEP39208A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
MEP-392/08A 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION MEP39208A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01307757 2001-09-12
PCT/GB2002/004158 WO2003022302A2 (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Publications (1)

Publication Number Publication Date
MEP39208A true MEP39208A (en) 2011-02-10

Family

ID=8182261

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-392/08A MEP39208A (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Country Status (19)

Country Link
US (1) US7405197B2 (pl)
EP (1) EP1425032A2 (pl)
JP (1) JP2005501918A (pl)
KR (1) KR20040032954A (pl)
CN (1) CN100536912C (pl)
AR (1) AR036592A1 (pl)
BR (1) BR0212429A (pl)
CA (1) CA2457849A1 (pl)
EA (1) EA009330B1 (pl)
HR (1) HRP20040087A2 (pl)
IL (1) IL160780A0 (pl)
ME (1) MEP39208A (pl)
MX (1) MXPA04002256A (pl)
NO (1) NO20040991L (pl)
PL (1) PL369098A1 (pl)
RS (1) RS21004A (pl)
UA (1) UA82650C2 (pl)
WO (1) WO2003022302A2 (pl)
ZA (1) ZA200400835B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE416783T1 (de) * 2003-02-07 2008-12-15 Austria Wirtschaftsserv Gmbh Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20150273020A1 (en) * 2007-05-11 2015-10-01 Lori R. Bernstein Hormone Normalization Therapy and Uses Therefor
ATE555721T1 (de) * 2009-04-23 2012-05-15 Hoffmann La Roche Verfahren und gerät zur ermittlung von empfehlungen für wirkstoffdosierungen anhand von messserien zumindest eines physiologischen parameters eines patienten
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
WO2012131306A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) * 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
BR112014001274A2 (pt) 2011-07-18 2017-04-18 Arts Biologics As composto de hormônio luteinizante, e, composição farmacêutica
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
MX2015004940A (es) 2012-10-18 2015-12-09 Neuralight Hd Llc Tratamiento de depresion y ptsd.
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CA3035055A1 (en) 2016-08-29 2018-03-08 Progena, Inc. Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of ivf patient
RU2646578C1 (ru) * 2017-02-13 2018-03-05 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия им. С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ повышения эффективности имплантации эмбриона в естественном цикле зачатия и в протоколах вспомогательных репродуктивных технологий
CN109431647B (zh) * 2018-09-20 2020-10-30 华中农业大学 一种杂交水牛同期发情-定时输精的处理方法
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
AU2021218895A1 (en) 2020-02-10 2022-09-15 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
TW202210096A (zh) * 2020-05-29 2022-03-16 荷蘭商菲林公司 治療不育症之方法
WO2026018221A1 (en) 2024-07-18 2026-01-22 ReproNovo SA Crystalline compositions for improving embryo implantation and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
ES2247710T3 (es) * 1997-06-20 2006-03-01 Akzo Nobel N.V. Antagonista de gonadotropina.
ZA987497B (en) * 1997-09-08 1999-02-23 Akzo Nobel Nv Expression of gonadotropins in dictyostelium
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
CN1353617A (zh) * 1999-02-24 2002-06-12 诺沃挪第克公司 不孕症的治疗
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
TR200401810T4 (tr) * 2000-01-27 2004-09-21 Applied Research Systems Ars Holding N. V. Kısırlık tedavisinde fsh'ın kullanılması

Also Published As

Publication number Publication date
UA82650C2 (uk) 2008-05-12
HK1067867A1 (zh) 2005-04-22
ZA200400835B (en) 2005-04-26
MXPA04002256A (es) 2004-07-23
EA200400427A1 (ru) 2004-08-26
EA009330B1 (ru) 2007-12-28
BR0212429A (pt) 2004-10-26
IL160780A0 (en) 2004-08-31
EP1425032A2 (en) 2004-06-09
HRP20040087A2 (en) 2004-12-31
US20050065069A1 (en) 2005-03-24
CA2457849A1 (en) 2003-03-20
AR036592A1 (es) 2004-09-22
KR20040032954A (ko) 2004-04-17
CN100536912C (zh) 2009-09-09
WO2003022302A2 (en) 2003-03-20
RS21004A (sr) 2006-12-15
US7405197B2 (en) 2008-07-29
JP2005501918A (ja) 2005-01-20
CN1553808A (zh) 2004-12-08
WO2003022302A3 (en) 2003-12-18
PL369098A1 (pl) 2005-04-18
NO20040991L (no) 2004-03-08

Similar Documents

Publication Publication Date Title
MXPA04002256A (es) Uso de gonadotropina corionica humana (gch) en hiperestimulacion ovarica controlada.
SE0100901D0 (sv) New composition
BR0215405A (pt) Composições e processos de uso de collajolie
BR0317715A (pt) Composições e processos de uso de collajolie
ATE337775T1 (de) Strukturen und zusammensetzungen zur erhöhung der stabilität von aktiven peroxiden
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
CY1108446T1 (el) Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
ATE291754T1 (de) Verhindern der unerwuenschten externen erfassung von operationen in integrierten digitalschaltungen
MEP38708A (en) Use of hcg and lh in controlled ovarian hyperstimulation
AU6276301A (en) A variable region of the monoclonal antibody against the hbv s-surface antigen and a gene encoding the same
ATE430403T1 (de) Synchronisierter gesteuerter oszillationsmodulator
DE60219337D1 (de) Gewebe
DE60135778D1 (de) Okklusionsvorrichtung
DK1161239T3 (da) 3- cyclopropylmethoxy-4-difluormethoxy-N-(3,5-dichlorpyrid-4-yl)benzamid til behandling af dissemineret sklerose
DK1274426T3 (da) Anvendelse af thioamidoxazolidinoner til behandling af knogleresorption og osteoporose
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
DK1224166T3 (da) Fremgangsmåde til fremstilling af N-(4,5-bis-methansulfonyl-2-methyl-benzoyl)-guanidin-hydrochlorid
DK1390022T3 (da) Anvendelse af 4-(2-fluorphenyl)-6-methyl-2-(1-piperazinyl)thieno (2,3-D)pyrimidin til behandling af smerte
DK1368478T3 (da) Polypeptid, der fremkalder HIV-neutraliserende antistoffer
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
WO2002057248A3 (en) Inhibitors of cruzipain and other cysteine proteases
WO2002042413A3 (en) Methods and compositions involved in groucho-mediated differentiation
FI4950U1 (fi) Keraaminen tiili
Tatl DDA LINE ALGORITHM